EA201591781A1 - Химические соединения - Google Patents

Химические соединения

Info

Publication number
EA201591781A1
EA201591781A1 EA201591781A EA201591781A EA201591781A1 EA 201591781 A1 EA201591781 A1 EA 201591781A1 EA 201591781 A EA201591781 A EA 201591781A EA 201591781 A EA201591781 A EA 201591781A EA 201591781 A1 EA201591781 A1 EA 201591781A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemical compounds
compositions
treatment
compounds
solvates
Prior art date
Application number
EA201591781A
Other languages
English (en)
Other versions
EA029771B1 (ru
Inventor
Хоакин Пастор Фернандес
Оскар Фернандес-Капетильо Руис
Соня Мартинес Гонсалес
Кармен Бланко Апарисио
Мария дель Росарио Рико Феррейра
Луис Игнасио Толедо Ласаро
Сонсолес Родригес Аристеги
Матильде Мурга Коста
Кармен Варела Бусто
Андрес Хоакин Лопес Контрерас
Оливер Реннер
Мария Ньето Солер
Давид Альваро Себриан Муньос
Original Assignee
Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii filed Critical Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii
Publication of EA201591781A1 publication Critical patent/EA201591781A1/ru
Publication of EA029771B1 publication Critical patent/EA029771B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

Описаны химические соединения, выбранные из соединений формулы (I)где R, Rи m имеют значения, перечисленные в описании, и их фармацевтически приемлемые соли, сольваты и стереоизомеры, которые являются ингибиторами ATR и потенциально могут применяться в лечении раковых заболеваний. Также описаны фармацевтические композиции данных химических соединений, комбинированные продукты, содержащие данные химические соединения, применение описанных композиций в качестве терапевтических средств и способы лечения с применением описанных композиций.
EA201591781A 2013-03-15 2014-03-14 Химические соединения EA029771B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15
PCT/GB2014/050825 WO2014140644A1 (en) 2013-03-15 2014-03-14 Chemical entities

Publications (2)

Publication Number Publication Date
EA201591781A1 true EA201591781A1 (ru) 2016-02-29
EA029771B1 EA029771B1 (ru) 2018-05-31

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591781A EA029771B1 (ru) 2013-03-15 2014-03-14 Химические соединения

Country Status (32)

Country Link
US (1) US9453031B2 (ru)
EP (1) EP2970332B1 (ru)
JP (1) JP6379115B2 (ru)
KR (1) KR102206318B1 (ru)
CN (1) CN105051047B (ru)
AR (1) AR095443A1 (ru)
AU (1) AU2014229735B2 (ru)
BR (1) BR112015023060B1 (ru)
CA (1) CA2904768C (ru)
CL (1) CL2015002591A1 (ru)
CY (1) CY1120619T1 (ru)
DK (1) DK2970332T3 (ru)
EA (1) EA029771B1 (ru)
ES (1) ES2670674T3 (ru)
HK (1) HK1215021A1 (ru)
HR (1) HRP20180839T1 (ru)
HU (1) HUE037685T2 (ru)
IL (1) IL240708B (ru)
LT (1) LT2970332T (ru)
MX (1) MX368056B (ru)
NO (1) NO2970332T3 (ru)
NZ (1) NZ711038A (ru)
PE (1) PE20152007A1 (ru)
PH (1) PH12015502159B1 (ru)
PL (1) PL2970332T3 (ru)
PT (1) PT2970332T (ru)
RS (1) RS57216B1 (ru)
SG (1) SG11201507555PA (ru)
SI (1) SI2970332T1 (ru)
TW (1) TWI557131B (ru)
UA (1) UA118261C2 (ru)
WO (1) WO2014140644A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
NZ710079A (en) 2013-01-15 2020-01-31 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017202748A1 (en) * 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3090330A1 (en) * 2018-02-07 2019-08-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Atr inhibitor and application thereof
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021143821A1 (zh) * 2020-01-17 2021-07-22 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
JP2023545196A (ja) 2020-10-16 2023-10-26 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド 三複素環誘導体、その医薬組成物及び使用
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
JP4367866B2 (ja) 1997-02-12 2009-11-18 ザ リージェンツ オブ ジ ユニバーシティ オブ ミシガン 肺癌用のタンパク質マーカーおよびその使用
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE482946T1 (de) 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
MXPA02004366A (es) 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (ru) 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
EP2079744A1 (en) * 2006-10-30 2009-07-22 Novartis AG Imidazopyridazines as pi3k lipid kinase inhibitors
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
MX2012002059A (es) * 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
EP2585468A1 (en) * 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
TWI441824B (zh) * 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法

Also Published As

Publication number Publication date
MX368056B (es) 2019-09-18
WO2014140644A1 (en) 2014-09-18
EP2970332A1 (en) 2016-01-20
US20160024112A1 (en) 2016-01-28
AU2014229735B2 (en) 2018-08-09
AU2014229735A1 (en) 2015-09-03
CN105051047A (zh) 2015-11-11
JP2016510803A (ja) 2016-04-11
AR095443A1 (es) 2015-10-14
EP2970332B1 (en) 2018-02-28
HRP20180839T1 (hr) 2018-06-29
US9453031B2 (en) 2016-09-27
ES2670674T3 (es) 2018-05-31
BR112015023060B1 (pt) 2022-07-05
PL2970332T3 (pl) 2018-08-31
RS57216B1 (sr) 2018-07-31
TW201446772A (zh) 2014-12-16
IL240708B (en) 2019-08-29
DK2970332T3 (en) 2018-05-22
TWI557131B (zh) 2016-11-11
KR20150129741A (ko) 2015-11-20
PH12015502159A1 (en) 2016-01-25
SG11201507555PA (en) 2015-10-29
HK1215021A1 (zh) 2016-08-12
LT2970332T (lt) 2018-06-11
KR102206318B1 (ko) 2021-01-25
IL240708A0 (en) 2015-10-29
HUE037685T2 (hu) 2018-09-28
SI2970332T1 (en) 2018-06-29
CA2904768C (en) 2021-07-27
UA118261C2 (uk) 2018-12-26
JP6379115B2 (ja) 2018-08-22
CN105051047B (zh) 2017-12-15
PE20152007A1 (es) 2016-02-04
NZ711038A (en) 2020-02-28
CA2904768A1 (en) 2014-09-18
BR112015023060A2 (pt) 2017-07-18
EA029771B1 (ru) 2018-05-31
CY1120619T1 (el) 2019-12-11
CL2015002591A1 (es) 2016-02-05
PH12015502159B1 (en) 2016-01-25
MX2015011549A (es) 2016-05-31
NO2970332T3 (ru) 2018-07-28
PT2970332T (pt) 2018-05-25

Similar Documents

Publication Publication Date Title
EA201591781A1 (ru) Химические соединения
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
PH12017502141A1 (en) Compounds and their methods of use
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
MD4650B1 (ru) Производные хиназолина, используемые при лечении ВИЧ
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
TW201613864A (en) Novel compounds
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201790604A1 (ru) Ингибиторы гистондеметилазы
EA201590347A1 (ru) Азагетероциклы в качестве ингибиторов bir2 и/или bir3
IN2015DN02109A (ru)
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM